As a result, when the second dose was given too soon after the first dose in immunocompromised individuals, due to reduced levels of CD4+ T cells and therefore slower activation of B cells, the production of neutralizing antibodies from plasma cells could be thwarted, thereby rendering an individual vulnerable to infection. The gene discussed is CD4; the disease is infection.